Evidence map›Paper›PMID 38136439›Full record

ArticleCancers2023

Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma.

Annick Laruelle, Claudia Manini, José I López, André Rocha

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 3 countries.

Annick LaruelleDepartment of Economic Analysis, University of the Basque Country (UPV/EHU), 48015 Bilbao, Spain.ORCID 0000-0002-7065-7070
Claudia ManiniDepartment of Pathology, San Giovanni Bosco Hospital, ASL Città di Torino, 10154 Turin, Italy.ORCID 0000-0002-5823-7137
José I LópezBiomarkers in Cancer, Biocruces-Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0003-0842-5348
André RochaDepartment of Industrial Engineering, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro CEP22451-900, Brazil.ORCID 0000-0001-8246-6039
BioCruces Health research Institute · ESIkerbasque · ESOspedale San Giovanni Bosco · ITPontifícia Universidade Católica do Rio de Janeiro · BR

Funding

Basque Government Research Group IT1697-22Ministerio de Ciencia, Tecnología y Telecomunicaciones MCIN/ AEI/10.13039/ 501100011033National Council for Scientific and Technological Development 307437/2019-1
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness. The results show that the fittest clone in a heterogeneous environment is fitter than the clone in a homogeneous context in the early phases of tumor evolution. Early and late periods of tumor evolution in CCRCC are also compared. The study shows the convergence of mathematical, histological, and genomics studies with respect to clonal aggressiveness in different periods of the natural history of CCRCC. Such convergence highlights the importance of multidisciplinary approaches for obtaining a better understanding of the intricacies of cancer.

Indexed as

cancer evolutionclear cell renal cell carcinomagame theoryintratumor heterogeneity

Identifiers

PMID38136439
PMCPMC10742011
OpenAlexW4389919255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.